To observe the safety and effectiveness of recombinant human growth hormone (rhGH) replacement therapy (GHRT) in postoperative craniopharyngioma (CP) children.
Safety and effectiveness of recombinant human growth hormone replacement in postoperative craniopharyngioma children Zhang-qian Zheng * , Di-jing Zhi, Shui-xian Shen, Fei-hong Luo, Zhu-hui Zhao, Zhong Lu, Rong Ye, Ruo-qian Cheng, Xiao-jing Li From 7th APPES Biennial Scientific Meeting Nusa Dua, Bali. 14-17 November 2012
Aims
To observe the safety and effectiveness of recombinant human growth hormone (rhGH) replacement therapy (GHRT) in postoperative craniopharyngioma (CP) children.
Subjects and methods
We reviewed the records for all patients undergoing GHRT at our hospital over the study period. Patients were included if they had received CP resection, GHRT for at least 12 months, and records of serial magnetic resonance imaging data and data for treatment, pituitary hormone profiles and growth chart were available. GHnaïve control patients were selected from our hospital database of patients carried out the same surgery. Patients were matched for date of surgery, age, site of primary diagnosis and sex.
Results
18 patients were recruited with growth hormone deficiency. In treatment group, all patients all gained acceleration in growth velocity and elevated growth factors level. There were no recurrent tumors found in both groups.
Conclusions
Our study demonstrates no increased risk for recurrent in patients receiving GHRT, thus supporting a high safety profile of GHRT in postoperative craniopharyngioma children. Additionally, GHRT can provide a significantly change in growth velocity compared with control group.
